IRME · IR-Med, Inc.
$0.00
At close · Jul 24
Going-concern doubt
— flagged Aug 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“For the six months ended June 30, 2025, and as of the date of this report, we assessed our financial condition and concluded that based on our current and projected cash resources and commitments, as well as other factors mentioned above, there is a substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2025
Market Cap
$162,201
Shares
77.24M
IRME metrics
33 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.00
Market cap
$162,201
Price action
19 metricsPrice change (1W)
+90.9%
Price change (30D)
—
Price change (3M)
—
Price change (6M)
+110.0%
Price change (YTD)
-93.0%
Price change (1Y)
-91.5%
Trailing year
Price change (5Y)
—
52-week high
$0.05
52-week low
$0.00
Change from 52-week high
-95.8%
Change from 52-week low
+110.0%
Annualized volatility
1,061.4%
Beta
—
RSI (14D)
36.3
Price vs SMA 50
-93.6%
Price vs SMA 200
-99.6%
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—
Company
3 metricsSector
Healthcare
Industry
Medical Devices
Shares outstanding
77.24M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,448.8%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$1.46M
Net income (TTM)
−$2.35M
Trailing 12 months
Diluted EPS (TTM)
$-0.03
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+4.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-1,342.9%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$63,000
Latest balance sheet
Cash & equivalents
$63,000
Total assets
$175,000
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$837,000
Capital expenditures (TTM)
$50,000
R&D (TTM)
$535,000
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Short interest
3 metricsShort interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged